OPEN LETTER TO DR. DAVID DALTON, CEO OF UNIVEC, INC. (UNVC)
Date: [Insert Today’s Date]
To: Dr. David Dalton
Chairman and Chief Executive Officer
Univec, Inc.
9722 Groffs Mills Drive, Suite 116
Owings Mills, MD 21117
Dear Dr. Dalton,
As long-standing and concerned shareholders of Univec, Inc., we respectfully submit this letter to express serious concerns and request clarity regarding the company’s strategic direction, communication practices, and financial condition.
Over the past several years, Univec has:
• Remained silent to the public market, with no shareholder letters, updates, or investor calls
• Issued over 1 billion shares in 2021–2022 without follow-up on their intended use
• Accumulated over $14 million in payroll liabilities
• Reported minimal to no revenue until FY 2024
• Failed to provide updates on longstanding claims—such as the Hopkins Bayview collaboration
We understand the challenges small-cap companies face. However, your continued silence, despite being the majority shareholder and CEO, is unacceptable by any standard of responsible governance. Shareholders deserve:
1. A clear, honest update on the operational status of Univec, including milestones achieved or delayed.
2. Explanation of past stock issuances, including to Bridgeview Capital and for conversions of insider compensation.
3. A realistic plan forward: Is Univec actively pursuing revenue-generating opportunities or preparing for a strategic event (e.g., acquisition, merger, or closure)?
4. Timeline and scope of any product commercialization, facility build-outs, or sales channel development.
5. A commitment to quarterly communication moving forward—regardless of financial materiality.
This silence erodes trust. It undermines shareholder value. And it calls into question the long-term intent behind the public listing of Univec.
We are not hostile—we are invested. We believe your medical background and previous industry experience still hold promise if matched with transparency and accountability. But without meaningful engagement, many shareholders are forced to reconsider their confidence in leadership.
We ask that you issue a formal shareholder update within the next 30 days and open a channel for investor relations inquiries—even if initially limited to email updates or pre-recorded briefings.
Respectfully,
[Name]
[Email / Phone (optional)]
Shareholder, UNVC
[Share Count or Holder Since XXXX]
Date: [Insert Today’s Date]
To: Dr. David Dalton
Chairman and Chief Executive Officer
Univec, Inc.
9722 Groffs Mills Drive, Suite 116
Owings Mills, MD 21117
Dear Dr. Dalton,
As long-standing and concerned shareholders of Univec, Inc., we respectfully submit this letter to express serious concerns and request clarity regarding the company’s strategic direction, communication practices, and financial condition.
Over the past several years, Univec has:
• Remained silent to the public market, with no shareholder letters, updates, or investor calls
• Issued over 1 billion shares in 2021–2022 without follow-up on their intended use
• Accumulated over $14 million in payroll liabilities
• Reported minimal to no revenue until FY 2024
• Failed to provide updates on longstanding claims—such as the Hopkins Bayview collaboration
We understand the challenges small-cap companies face. However, your continued silence, despite being the majority shareholder and CEO, is unacceptable by any standard of responsible governance. Shareholders deserve:
1. A clear, honest update on the operational status of Univec, including milestones achieved or delayed.
2. Explanation of past stock issuances, including to Bridgeview Capital and for conversions of insider compensation.
3. A realistic plan forward: Is Univec actively pursuing revenue-generating opportunities or preparing for a strategic event (e.g., acquisition, merger, or closure)?
4. Timeline and scope of any product commercialization, facility build-outs, or sales channel development.
5. A commitment to quarterly communication moving forward—regardless of financial materiality.
This silence erodes trust. It undermines shareholder value. And it calls into question the long-term intent behind the public listing of Univec.
We are not hostile—we are invested. We believe your medical background and previous industry experience still hold promise if matched with transparency and accountability. But without meaningful engagement, many shareholders are forced to reconsider their confidence in leadership.
We ask that you issue a formal shareholder update within the next 30 days and open a channel for investor relations inquiries—even if initially limited to email updates or pre-recorded briefings.
Respectfully,
[Name]
[Email / Phone (optional)]
Shareholder, UNVC
[Share Count or Holder Since XXXX]
13
